Cargando…
Clinical next generation sequencing to identify actionable aberrations in a phase I program
PURPOSE: We determined the frequency of recurrent hotspot mutations in 46 cancer-related genes across tumor histologies in patients with advanced cancer. METHODS: We reviewed data from 500 consecutive patients who underwent genomic profiling on an IRB-approved prospective clinical protocol in the Ph...
Autores principales: | Boland, Genevieve M., Piha-Paul, Sarina A., Subbiah, Vivek, Routbort, Mark, Herbrich, Shelley M., Baggerly, Keith, Patel, Keyur P., Brusco, Lauren, Horombe, Chacha, Naing, Aung, Fu, Siqing, Hong, David S., Janku, Filip, Johnson, Amber, Broaddus, Russell, Luthra, Raja, Shaw, Kenna, Mendelsohn, John, Mills, Gordon B., Meric-Bernstam, Funda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652990/ https://www.ncbi.nlm.nih.gov/pubmed/26015395 |
Ejemplares similares
-
Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer
por: Wang, Zhijie, et al.
Publicado: (2017) -
Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic
por: Dembla, Vikas, et al.
Publicado: (2018) -
Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
por: Groisberg, Roman, et al.
Publicado: (2017) -
Correction: A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory
por: Arango, Natalia Paez, et al.
Publicado: (2019) -
A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory
por: Arango, Natalia Paez, et al.
Publicado: (2017)